Index -
P/E 7.16
EPS (ttm) 7.00
Insider Own 91.82%
Shs Outstand 484.00M
Perf Week 3.59%
Market Cap 24.28B
Forward P/E 12.12
EPS next Y 4.14
Insider Trans 0.00%
Shs Float 39.61M
Perf Month -0.10%
Income 3.39B
PEG -
EPS next Q 0.97
Inst Own 46.31%
Short Float 1.99%
Perf Quarter -4.86%
Sales 9.66B
P/S 2.51
EPS this Y -44.84%
Inst Trans -0.29%
Short Ratio 4.00
Perf Half Y -9.19%
Book/sh 2.14
P/B 23.39
EPS next Y 7.94%
ROA 17.97%
Short Interest 0.79M
Perf Year 14.15%
Cash/sh 1.30
P/C 38.48
EPS next 5Y -7.70%
ROE -
52W Range 42.80 - 62.02
Perf YTD 1.26%
Dividend Est. 3.33 (6.63% )
P/FCF 8.40
EPS past 5Y 97.79%
ROI 20.26%
52W High -19.13%
Beta 0.67
Dividend TTM 0.78 (1.55%)
Quick Ratio 0.92
Sales past 5Y 18.21%
Gross Margin 47.80%
52W Low 17.19%
ATR (14) 1.15
Dividend Ex-Date May 08, 2024
Current Ratio 1.01
EPS Y/Y TTM 115.51%
Oper. Margin 46.70%
RSI (14) 57.63
Volatility 2.76% 2.38%
Employees 1605
Debt/Eq 15.42
Sales Y/Y TTM -43.30%
Profit Margin 35.08%
Recom 4.00
Target Price 49.82
Option/Short Yes / Yes
LT Debt/Eq 15.12
EPS Q/Q -69.77%
Payout 59.39%
Rel Volume 0.78
Prev Close 49.06
Sales Surprise 8.66%
EPS Surprise 62.17%
Sales Q/Q -43.11%
Earnings Feb 22 BMO
Avg Volume 197.09K
Price 50.16
SMA20 4.32%
SMA50 2.55%
SMA200 -3.77%
Trades
Volume 152,857
Change 2.24%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-22-24 Upgrade
Stifel
Sell → Hold
Nov-03-23 Downgrade
Stifel
Hold → Sell
$53
Oct-06-23 Resumed
Goldman
Sell
$48
Jul-19-23 Upgrade
UBS
Neutral → Buy
$57
Jun-01-23 Downgrade
Wolfe Research
Peer Perform → Underperform
$43
Dec-09-22 Initiated
Citigroup
Sell
$47
Aug-11-22 Upgrade
Evercore ISI
In-line → Outperform
$54 → $55
May-31-22 Downgrade
Wells Fargo
Equal Weight → Underweight
$55
Feb-01-22 Downgrade
UBS
Buy → Neutral
$50
Jan-14-22 Downgrade
Goldman
Buy → Neutral
$45
Nov-30-21 Downgrade
Barclays
Equal Weight → Underweight
$48
Jul-20-21 Downgrade
Barclays
Overweight → Equal Weight
$45
Jun-14-21 Upgrade
Goldman
Neutral → Buy
$56
Mar-12-21 Downgrade
JP Morgan
Neutral → Underweight
$44
Nov-19-20 Downgrade
Credit Suisse
Neutral → Underperform
$31 → $32
Oct-20-20 Initiated
Wells Fargo
Equal Weight
Aug-26-20 Downgrade
Citigroup
Buy → Neutral
$49 → $40
Jun-09-20 Downgrade
BMO Capital Markets
Market Perform → Underperform
$34
Mar-24-20 Upgrade
Barclays
Equal Weight → Overweight
$31
Mar-12-20 Upgrade
Credit Suisse
Underperform → Neutral
Show Previous Ratings
Apr-29-24 08:30AM
Apr-05-24 08:00AM
Mar-28-24 04:30PM
Feb-23-24 06:55PM
Feb-22-24 04:43PM
07:30AM
Loading…
07:30AM
Jan-31-24 08:30AM
Jan-26-24 05:14PM
08:30AM
Dec-12-23 07:18PM
Nov-29-23 08:30AM
Nov-17-23 07:15PM
Nov-02-23 03:38PM
07:30AM
Oct-27-23 04:05PM
02:11PM
Loading…
Sep-29-23 02:11PM
Sep-26-23 05:11PM
Sep-18-23 11:05AM
Sep-07-23 01:44PM
Aug-03-23 02:47PM
07:30AM
Jul-28-23 08:30AM
Jul-13-23 06:57PM
Jun-06-23 04:08PM
08:13AM
May-02-23 07:07PM
07:30AM
Apr-28-23 08:00AM
Mar-15-23 07:17PM
(Morningstar Research) -5.88%
Mar-01-23 07:01PM
04:01PM
Loading…
Feb-24-23 04:01PM
Feb-23-23 11:36PM
(Morningstar Research) +7.07%
07:30AM
07:15AM
Jan-27-23 08:00AM
Jan-05-23 12:05PM
Jan-03-23 07:07PM
Dec-14-22 09:00AM
Dec-12-22 04:24PM
(Investor's Business Daily)
Dec-09-22 02:51PM
09:11AM
Dec-08-22 11:30AM
Dec-05-22 08:20AM
(Investor's Business Daily)
07:13AM
(Investor's Business Daily)
Dec-04-22 07:00PM
Dec-02-22 05:08PM
(Investor's Business Daily)
02:10PM
Nov-30-22 08:00AM
(Investor's Business Daily)
Nov-29-22 06:19PM
09:00AM
07:23AM
Nov-28-22 07:40AM
Nov-26-22 01:41PM
Nov-24-22 07:00PM
09:28AM
08:52AM
Nov-23-22 05:00PM
Nov-22-22 09:47AM
Nov-21-22 08:31AM
Nov-18-22 11:32AM
10:36AM
09:41AM
09:29AM
09:00AM
Nov-17-22 12:19PM
09:02AM
07:40AM
(Investor's Business Daily)
Nov-16-22 05:20PM
(Investor's Business Daily)
03:41PM
12:45PM
11:20AM
09:54AM
09:38AM
Nov-15-22 03:03PM
10:50AM
09:49AM
Nov-14-22 04:57PM
02:54PM
01:08PM
01:08PM
08:56AM
08:19AM
07:41AM
Nov-12-22 07:30AM
Nov-11-22 11:36AM
10:00AM
08:44AM
Nov-10-22 10:40PM
12:05PM
09:02AM
Nov-09-22 07:00PM
Nov-08-22 05:08PM
03:55PM
11:10AM
09:15AM
Nov-07-22 11:00PM
05:05PM
12:20PM
09:54AM
(Investor's Business Daily)
09:00AM
Cheniere Energy Partners LP engages in the operations of liquefied natural gas. The company was founded in 2006 and is headquartered in Houston, TX.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Grindal Corey EVP & Chief Operating Officer May 25 '23 Sale 45.93 7,649 351,304 0 May 26 05:18 PM
Index S&P 500
P/E 24.97
EPS (ttm) 9.21
Insider Own 2.03%
Shs Outstand 51.34M
Perf Week 0.91%
Market Cap 11.80B
Forward P/E 18.48
EPS next Y 12.44
Insider Trans -3.04%
Shs Float 50.31M
Perf Month -11.35%
Income 474.62M
PEG 2.72
EPS next Q 2.06
Inst Own 101.19%
Short Float 3.79%
Perf Quarter 4.71%
Sales 4.13B
P/S 2.86
EPS this Y 3.35%
Inst Trans 3.21%
Short Ratio 3.58
Perf Half Y 36.55%
Book/sh 70.06
P/B 3.28
EPS next Y 12.83%
ROA 6.01%
Short Interest 1.91M
Perf Year 21.63%
Cash/sh 5.50
P/C 41.78
EPS next 5Y 9.19%
ROE 14.44%
52W Range 161.65 - 275.00
Perf YTD -2.75%
Dividend Est. -
P/FCF 32.31
EPS past 5Y 14.84%
ROI 7.12%
52W High -16.40%
Beta 1.43
Dividend TTM -
Quick Ratio 1.16
Sales past 5Y 12.89%
Gross Margin 33.56%
52W Low 42.21%
ATR (14) 7.36
Dividend Ex-Date -
Current Ratio 1.52
EPS Y/Y TTM -3.17%
Oper. Margin 15.82%
RSI (14) 39.56
Volatility 2.85% 2.91%
Employees 21800
Debt/Eq 0.87
Sales Y/Y TTM 3.86%
Profit Margin 11.49%
Recom 1.94
Target Price 271.56
Option/Short Yes / Yes
LT Debt/Eq 0.85
EPS Q/Q -0.65%
Payout 0.00%
Rel Volume 0.77
Prev Close 232.69
Sales Surprise 2.24%
EPS Surprise 2.42%
Sales Q/Q -7.85%
Earnings May 09 BMO
Avg Volume 533.62K
Price 229.89
SMA20 -3.54%
SMA50 -8.87%
SMA200 6.03%
Trades
Volume 409,225
Change -1.20%
Date
Action
Analyst
Rating Change
Price Target Change
Feb-15-24 Downgrade
Guggenheim
Buy → Neutral
Sep-13-23 Initiated
TD Cowen
Market Perform
$212
Jul-10-23 Downgrade
Citigroup
Buy → Neutral
$260 → $225
Feb-23-23 Upgrade
Guggenheim
Neutral → Buy
$255
Jan-12-23 Downgrade
Jefferies
Buy → Hold
Sep-30-22 Upgrade
Jefferies
Hold → Buy
$240
Aug-25-22 Initiated
Credit Suisse
Outperform
$285
Aug-04-22 Downgrade
Morgan Stanley
Overweight → Equal-Weight
$350 → $250
May-24-22 Initiated
Guggenheim
Neutral
Apr-25-22 Downgrade
Jefferies
Buy → Hold
$370 → $280
Apr-07-22 Initiated
Stephens
Overweight
$377
Feb-17-22 Upgrade
Citigroup
Neutral → Buy
$400
Feb-17-22 Reiterated
UBS
Buy
$465 → $420
Feb-17-22 Reiterated
Morgan Stanley
Overweight
$465 → $430
Feb-17-22 Reiterated
Deutsche Bank
Buy
$409 → $350
Feb-17-22 Reiterated
BofA Securities
Buy
$445 → $400
Aug-05-21 Resumed
Credit Suisse
Neutral
$385
Dec-16-20 Downgrade
Citigroup
Buy → Neutral
$270 → $250
Sep-10-20 Upgrade
Jefferies
Hold → Buy
$254
Jul-01-20 Upgrade
BofA Securities
Neutral → Buy
$192
Show Previous Ratings
Today 08:00AM
Apr-24-24 12:47PM
Apr-22-24 08:00AM
Apr-18-24 12:09PM
Apr-16-24 11:50AM
08:00AM
Loading…
08:00AM
Apr-12-24 08:00AM
Apr-11-24 09:10AM
08:00AM
Apr-09-24 08:00AM
Apr-04-24 08:00AM
Apr-01-24 08:00AM
Mar-27-24 08:00AM
Mar-26-24 09:39AM
Mar-23-24 09:00AM
(The Wall Street Journal)
08:00AM
Loading…
Mar-21-24 08:00AM
Mar-15-24 11:30AM
10:30AM
Mar-14-24 09:46AM
08:00AM
Mar-12-24 08:00AM
12:11AM
Mar-07-24 12:27PM
Mar-01-24 11:32PM
Feb-29-24 02:00AM
Feb-26-24 08:41AM
Feb-21-24 10:40AM
08:00AM
Feb-20-24 01:15PM
08:08AM
01:00PM
Loading…
Feb-15-24 01:00PM
10:54AM
12:38AM
Feb-14-24 08:06PM
(Morningstar Research) +11.30%
09:30AM
09:30AM
08:09AM
07:19AM
(Associated Press Finance)
07:00AM
Feb-13-24 08:20AM
Feb-09-24 09:15AM
Feb-01-24 10:08AM
Jan-29-24 08:00AM
Jan-27-24 09:00AM
Jan-24-24 04:30PM
Jan-23-24 04:30PM
Jan-18-24 09:10AM
Jan-16-24 08:00AM
(Investor's Business Daily)
08:00AM
Jan-12-24 02:02PM
09:00AM
Jan-08-24 08:00AM
Jan-02-24 09:00AM
(The Wall Street Journal)
Dec-19-23 08:01AM
Dec-18-23 08:00AM
Dec-13-23 08:29AM
Dec-12-23 08:00AM
Dec-08-23 11:30AM
Dec-07-23 01:53PM
Dec-05-23 07:29AM
Dec-02-23 01:05AM
Nov-29-23 07:57AM
Nov-28-23 08:00AM
Nov-27-23 08:30AM
Nov-22-23 03:04AM
Nov-20-23 08:34PM
Nov-17-23 06:45PM
08:40AM
Nov-16-23 12:59PM
08:00AM
Nov-13-23 09:04AM
Nov-10-23 12:11PM
Nov-09-23 05:14PM
08:00AM
01:33AM
(Thomson Reuters StreetEvents)
Nov-08-23 03:20PM
10:59AM
09:30AM
08:54AM
08:26AM
07:06AM
(Associated Press Finance)
07:00AM
Nov-06-23 10:27AM
Nov-01-23 10:01AM
09:13AM
Oct-25-23 08:06PM
(Morningstar Research) -5.97%
Oct-24-23 12:10PM
Oct-23-23 10:10AM
Oct-19-23 08:00AM
Oct-16-23 08:30AM
08:00AM
Oct-11-23 08:00AM
Oct-10-23 09:10AM
Oct-05-23 12:55PM
Oct-02-23 11:35AM
Sep-27-23 12:04PM
Sep-26-23 08:02AM
08:00AM
Sep-25-23 11:40AM
08:00AM
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions. The RMS segment includes its insourcing solutions business and Charles River accelerator and development lab footprint. The DSA segment offers regulatory-required safety testing of potential new drugs, vaccines, industrial and agricultural chemicals, consumer products, veterinary medicines, and medical devices. The Manufacturing Solutions segment focuses on microbial solutions and biologics solutions. The company was founded by Henry L. Foster in 1947 and is headquartered in Wilmington, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Knell Michael Gunnar CSVP&Chief Accounting Officer Mar 08 '24 Sale 267.52 808 216,156 7,024 Mar 11 04:42 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Mar 04 '24 Sale 261.05 2,750 717,890 7,832 Mar 05 04:54 PM Creamer Victoria L EVP & Chief People Officer Feb 29 '24 Sale 253.70 5,000 1,268,500 13,550 Mar 01 05:37 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Feb 29 '24 Sale 253.45 3,786 959,545 4,792 Mar 04 04:09 PM Barbo William D Corporate Executive VP & CCO Feb 22 '24 Sale 248.50 4,050 1,006,425 22,879 Feb 23 04:57 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Feb 15 '24 Option Exercise 144.67 5,882 850,949 8,478 Feb 20 05:32 PM Parisotto Shannon M CEVP, Disc & Safety Assessment Feb 15 '24 Sale 241.20 5,882 1,418,767 2,596 Feb 20 05:32 PM LaPlume Joseph W EVP, Corp Strategy & Develop Feb 15 '24 Sale 238.93 838 200,223 24,620 Feb 20 05:20 PM FOSTER JAMES C Chairman, President and CEO Jan 29 '24 Option Exercise 144.67 17,436 2,522,466 227,827 Jan 31 04:59 PM Girshick Birgit Corporate Executive VP & COO Jan 10 '24 Option Exercise 215.19 5,916 1,273,064 50,365 Jan 11 04:09 PM Creamer Victoria L EVP & Chief People Officer Dec 14 '23 Option Exercise 136.70 5,526 755,388 22,032 Dec 18 04:07 PM Creamer Victoria L EVP & Chief People Officer Dec 14 '23 Sale 225.00 5,526 1,243,350 16,506 Dec 18 04:07 PM LaPlume Joseph W EVP, Corp Strategy & Develop Nov 30 '23 Sale 197.73 1,850 365,800 23,133 Dec 01 04:10 PM Girshick Birgit Corporate Executive VP & COO Nov 20 '23 Buy 187.82 1,322 248,298 44,449 Nov 21 05:07 PM FOSTER JAMES C Chairman, President and CEO Nov 14 '23 Buy 178.05 5,620 1,000,641 202,643 Nov 15 09:23 AM LaPlume Joseph W EVP, Corp Strategy & Develop Nov 09 '23 Option Exercise 144.67 9,128 1,320,548 34,111 Nov 13 04:12 PM LaPlume Joseph W EVP, Corp Strategy & Develop Nov 09 '23 Sale 173.48 9,128 1,583,522 24,983 Nov 13 04:12 PM WALLMAN RICHARD F Director Aug 24 '23 Buy 198.79 1,000 198,786 1,000 Aug 29 04:23 PM Barbo William D Corporate Executive VP & CCO Aug 10 '23 Option Exercise 144.67 5,511 797,276 9,103 Aug 14 04:17 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Aug 10 '23 Option Exercise 144.67 1,471 212,810 11,411 Aug 14 04:15 PM Barbo William D Corporate Executive VP & CCO Aug 10 '23 Sale 217.24 5,763 1,251,954 3,592 Aug 14 04:17 PM Knell Michael Gunnar CSVP&Chief Accounting Officer Aug 10 '23 Sale 216.54 1,471 318,530 9,940 Aug 14 04:15 PM LaPlume Joseph W EVP, Corp Strategy & Develop Aug 10 '23 Sale 216.52 700 151,564 24,983 Aug 14 04:11 PM LaPlume Joseph W EVP, Corp Strategy & Develop May 15 '23 Sale 190.39 345 65,685 24,026 May 16 02:18 PM LaPlume Joseph W EVP, Corp Strategy & Develop May 12 '23 Sale 193.03 959 185,116 24,371 May 15 02:49 PM MASSARO GEORGE Director May 11 '23 Sale 193.43 288 55,708 4,964 May 15 02:42 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite